Ayesha also talked about the FDA approval of AstraZeneca’s immunotherapy Imjudo for hepatocellular carcinoma (HCC), which is the most common type of Liver Cancer. The drug is indicated for use in combination with AstraZeneca’s PD-L1 inhibitor Imfinzi in adult patients with unresectable HCC. The new drug combination will be going up against Roche’s combo of Tecentriq and Avastin, which recently became the standard of care for HCC. Despite this, the Imjudo and Imfinzi approval offers another promising treatment option for HCC patients and is the first dual immunotherapy treatment regimen for this indication.
Read the full articles here:
Multiple Myeloma Drug Tecvayli Becomes First FDA-Approved Bispecific T Cell Antibody
AstraZeneca’s Immunotherapy Imjudo (tremelimumab) Wins FDA Approval for Liver Cancer
The weekly podcast is available for streaming every Wednesday on Spotify, Apple Music and wherever you stream your podcasts.
Subscribe to the Xtalks Life Science Podcast to never miss a new episode.
This post first appeared on Personalized Content Generation For Successful Webinars, please read the originial post: here
